Literature DB >> 29187303

Prevalence and characteristics of chronic kidney disease among Danish adults with cystic fibrosis.

Kristina H Berg1, Lene Ryom2, Daniel Faurholt-Jepsen2, Tania Pressler2, Terese L Katzenstein2.   

Abstract

BACKGROUND: With improved prognosis of CF, comorbidities including chronic kidney disease (CKD) are becoming increasingly important. Identification of those at highest CKD risk is hence a priority.
METHODS: In this cross-sectional study, adults with CF attending the Copenhagen CF Centre at Rigshospitalet with ≥2 measurements of serum creatinine from 2013 to 2015 were included. Data was obtained from an electronic CF database, which contains anonymised clinical and laboratory data on all individuals attending the clinic. CKD was defined as a confirmed (≥3months apart) estimated glomerular filtration rate≤60mL/min/1.73m2.
RESULTS: Of 181 individuals, the CKD prevalence was 2.7% and increased to 11% after inclusion of lung transplanted patients. Individuals with CKD were generally older (median 39 (IQR, 36-45) vs. 31 (IQR, 24-39) years; p<0.001), diabetic (86% vs. 41%, p<0.001), with longer median duration of chronic pulmonary infection (28.3 (20.0-35.8) vs. 20.0 (9.9-34.7) years; p=0.008) and with longer intravenous aminoglycosides use (606 (IQR, 455-917) vs. 273 (IQR, 91-826) days, p=0.005).
CONCLUSIONS: The CKD prevalence is high and related to age, diabetes, chronic infection, transplantation and aminoglycosides use. These observations call for longitudinal studies investigating CKD predictors in adults with CF.
Copyright © 2017 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29187303     DOI: 10.1016/j.jcf.2017.11.001

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  10 in total

1.  Magnesium Status and Calcium/Magnesium Ratios in a Series of Cystic Fibrosis Patients.

Authors:  Marlene Fabiola Escobedo-Monge; Enrique Barrado; Joaquín Parodi-Román; María Antonieta Escobedo-Monge; Marianela Marcos-Temprano; José Manuel Marugán-Miguelsanz
Journal:  Nutrients       Date:  2022-04-25       Impact factor: 6.706

2.  Renal Function in Patients with Cystic Fibrosis: A Single-Center Study.

Authors:  Marta Rachel; Sabina Galiniak; Marek Biesiadecki; Agnieszka Gala-Błądzińska
Journal:  Int J Environ Res Public Health       Date:  2022-04-29       Impact factor: 4.614

Review 3.  The future of cystic fibrosis care: a global perspective.

Authors:  Scott C Bell; Marcus A Mall; Hector Gutierrez; Milan Macek; Susan Madge; Jane C Davies; Pierre-Régis Burgel; Elizabeth Tullis; Claudio Castaños; Carlo Castellani; Catherine A Byrnes; Fiona Cathcart; Sanjay H Chotirmall; Rebecca Cosgriff; Irmgard Eichler; Isabelle Fajac; Christopher H Goss; Pavel Drevinek; Philip M Farrell; Anna M Gravelle; Trudy Havermans; Nicole Mayer-Hamblett; Nataliya Kashirskaya; Eitan Kerem; Joseph L Mathew; Edward F McKone; Lutz Naehrlich; Samya Z Nasr; Gabriela R Oates; Ciaran O'Neill; Ulrike Pypops; Karen S Raraigh; Steven M Rowe; Kevin W Southern; Sheila Sivam; Anne L Stephenson; Marco Zampoli; Felix Ratjen
Journal:  Lancet Respir Med       Date:  2019-09-27       Impact factor: 30.700

Review 4.  Cystic Fibrosis-Related Diabetes.

Authors:  Kayani Kayani; Raihan Mohammed; Hasan Mohiaddin
Journal:  Front Endocrinol (Lausanne)       Date:  2018-02-20       Impact factor: 5.555

5.  Unknown Renal Impairment: A Rare Case of Inhaled Tobramycin Induced Acute Kidney Injury in a Cystic Fibrosis Patient.

Authors:  Tyler Miller; Cristina Pastuch; Lisa Garavaglia; Kelley Gannon; Anthony Parravani
Journal:  Antibiotics (Basel)       Date:  2021-04-12

Review 6.  Progress in precision medicine in cystic fibrosis: a focus on CFTR modulator therapy.

Authors:  Daniel H Tewkesbury; Rebecca C Robey; Peter J Barry
Journal:  Breathe (Sheff)       Date:  2021-12

7.  Retinopathy and microalbuminuria are common microvascular complications in cystic fibrosis-related diabetes.

Authors:  Punith Kempegowda; Harbinder Sunsoa; Joht S Chandan; Lauren M Quinn; Prashant M Amrelia; Syed Noman Atta; Sidrah Amir; Yee Suh Teh; Sabba Chaudhry; Anne de Bray; Rifat Rashid; Joanna L Whitehouse; Edward F Nash; Ateeq Syed
Journal:  Ther Adv Endocrinol Metab       Date:  2020-10-21       Impact factor: 3.565

8.  Synergistic Activity of Repurposed Peptide Drug Glatiramer Acetate with Tobramycin against Cystic Fibrosis Pseudomonas aeruginosa.

Authors:  Ronan A Murphy; Matthew Coates; Sophia Thrane; Akshay Sabnis; James Harrison; Silke Schelenz; Andrew M Edwards; Thomas Vorup-Jensen; Jane C Davies
Journal:  Microbiol Spectr       Date:  2022-06-21

9.  Combined Liver-Lung-Kidney Transplant in a Patient with Cystic Fibrosis.

Authors:  Lori Shah; Geoffrey Dube; Lorna Dove; Amy C McLaughlin; Jean Emond; Lloyd Rattner; Frank D'Ovidio; Emily DiMango
Journal:  Am J Case Rep       Date:  2021-06-24

10.  Copper and Copper/Zinc Ratio in a Series of Cystic Fibrosis Patients.

Authors:  Marlene Fabiola Escobedo-Monge; Enrique Barrado; Carmen Alonso Vicente; María Antonieta Escobedo-Monge; María Carmen Torres-Hinojal; José Manuel Marugán-Miguelsanz; María Paz Redondo Del Río
Journal:  Nutrients       Date:  2020-10-30       Impact factor: 5.717

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.